GlassScriptPhysician profile
Pamela Clark
NPI 1851364277
$15,026.44
in general payments reported to CMS, 2019-2025
26 companies · $75.55 in 2025
The $75.55 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $59.45 · 2021: $11K · 2022: $453 · 2023: $2,413 · 2024: $462 · 2025: $75.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,875 · Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,875.00 |
| Food and Beverage | $1,076.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13,288.79 | 2019-2023 | Sogroya, Norditropin |
| Abbvie INC. | $388.79 | 2021-2025 | Lupron Depot |
| Azurity Pharmaceuticals, INC. | $222.74 | 2022-2024 | Triptodur, Triptodur |
| Insulet Corporation | $158.53 | 2019-2023 | Omnipod |
| Abbott Laboratories | $120.41 | 2019-2024 | Freestyle Libre 3 |
| Pfizer INC. | $114.69 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $109.62 | 2024 | |
| Medtronic, INC. | $97.71 | 2024 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $61.64 | 2022-2023 | Imcivree |
| Endo Pharmaceuticals INC. | $53.04 | 2022-2023 | Supprelin |
| Stryker Corporation | $46.47 | 2025 | Flowtriever |
| Zealand Pharma US, INC. | $44.16 | 2021 | |
| Kyowa Kirin, INC. | $35.03 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $31.30 | 2022-2024 | Gvoke Hypopen |
| Eton Pharmaceuticals, INC. | $28.85 | 2023-2025 | Alkindi, Increlex, Khindivi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $23.81 | 2023 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $23.67 | 2023 | |
| Amneal Pharmaceuticals LLC | $23.06 | 2022 | |
| Biomarin Pharmaceutical INC. | $22.89 | 2021 | |
| Becton, Dickinson and Company | $21.65 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $20.60 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.15 | 2021 | |
| Neurocrine Biosciences, INC. | $19.87 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.44 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.70 | 2020 | |
| Legend Biotech USA INC. | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.